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Abstract: An effective therapeutic vaccine for the treatment of chronic hepatitis C virus (HCV)
infection, as an adjunct to newly developed directly-acting antivirals (DAA), or for the prevention of
reinfection, would significantly reduce the global burden of disease associated with chronic HCV
infection. A recombinant chimpanzee adenoviral (ChAd3) vector and a modified vaccinia Ankara
(MVA), encoding the non-structural proteins of HCV (NSmut), used in a heterologous prime/boost
regimen induced multi-specific, high-magnitude, durable HCV-specific CD4+ and CD8+ T-cell
responses in healthy volunteers, and was more immunogenic than a heterologous Ad regimen. We
now assess the immunogenicity of this vaccine regimen in HCV infected patients (including patients
with a low viral load suppressed with interferon/ribavirin therapy), determine T-cell cross-reactivity
to endogenous virus, and compare immunogenicity with that observed previously in both healthy
volunteers and in HCV infected patients vaccinated with the heterologous Ad regimen. Vaccination
of HCV infected patients with ChAd3-NSmut/MVA-NSmut was well tolerated. Vaccine-induced
HCV-specific T-cell responses were detected in 8/12 patients; however, CD4+ T-cell responses were
rarely detected, and the overall magnitude of HCV-specific T-cell responses was markedly reduced
when compared to vaccinated healthy volunteers. Furthermore, HCV-specific cells had a distinct
partially-functional phenotype (lower expression of activation markers, granzyme B, and TNFα
production, weaker in vitro proliferation, and higher Tim3 expression, with comparable Tbet and
Eomes expression) compared to healthy volunteers. Robust anti-vector T-cells and antibodies were
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induced, showing that there is no global defect in immunity. The level of viremia at the time of
vaccination did not correlate with the magnitude of the vaccine-induced T-cell response. Full-length,
next-generation sequencing of the circulating virus demonstrated that T-cells were only induced by
vaccination when there was a sequence mismatch between the autologous virus and the vaccine
immunogen. However, these T-cells were not cross-reactive with the endogenous viral variant
epitopes. Conversely, when there was complete homology between the immunogen and circulating
virus at a given epitope T-cells were not induced. T-cell induction following vaccination had no
significant impact on HCV viral load. In vitro T-cell culture experiments identified the presence
of T-cells at baseline that could be expanded by vaccination; thus, HCV-specific T-cells may have
been expanded from pre-existing low-level memory T-cell populations that had been exposed to
HCV antigens during natural infection, explaining the partial T-cell dysfunction. In conclusion,
vaccination with ChAd3-NSmut and MVA-NSmut prime/boost, a potent vaccine regimen previously
optimized in healthy volunteers was unable to reconstitute HCV-specific T-cell immunity in HCV
infected patients. This highlights the major challenge of overcoming T-cell exhaustion in the context
of persistent antigen exposure.
Keywords: therapeutic vaccination; adenovirus; modified vaccinia Ankara; immunotherapy; HCV;
T-cells; exhaustion
1. Introduction
Hepatitis C virus (HCV) infection is a leading cause of death and morbidity from liver disease
and, with approximately 185 million people infected, represents a significant global health problem [1].
HCV is able to persist in the majority of immune-competent hosts it infects, and this leads to a state of
chronic hepatic inflammation, which can progress to fibrosis and cirrhosis of the liver and, ultimately,
liver failure or hepatocellular carcinoma.
Despite great advances in the treatment options for HCV [2] there remains a compelling argument
for the continued development of not only prophylactic, but also therapeutic, candidate vaccines for
HCV [3]. It is likely that, globally, a significant proportion of HCV infected patients will not have
access to treatment and surveillance programs [4], as has been the case for antiretroviral therapy for
HIV [5], and reinfection is a problem in high-risk cohorts [6,7]. An effective stand-alone therapeutic
vaccine or, more likely, a vaccine to be used as an adjunct to IFN-free directly-acting antiviral therapy,
to reduce therapy duration and cost, or to prevent persistence on reinfection, remains a desirable
global health target.
A T-cell vaccine for HCV is a realistic goal since a significant number of individuals spontaneously
clear HCV in the setting of an appropriate immune response, and there is evidence of protective
immunological memory against HCV in chimpanzees and humans, where secondary infection is
associated with reductions in peak and duration of viraemia, hepatic inflammation, and an increased
rate of viral clearance [8–10]. Comparative analyses of individuals with distinct clinical outcomes have
been performed by several groups, and there is now some consensus on the immune response required
to prevent persistence of HCV, but there is no single correlate of protection (reviewed in [11,12]).
A strong, broad, and persistent HCV-specific T-cell response during acute infection is required for
spontaneous clearance [13–15]. T-cell dysfunction is a hallmark of chronic viral infection, including
T-cell exhaustion, inhibition by regulatory T-cells, and T-cell escape. Whether a T-cell vaccine can
overcome these obstacles, by enhancing existing weak responses or by generating de novo T-cell
responses once chronic disease is established is a fundamental question that will be addressed in
this study.
Previous immunotherapeutic vaccine approaches [16] have included HCV peptide vaccines [17],
recombinant yeast expressing an HCV NS3-core fusion protein [18], autologous dendritic cells loaded
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with lipopeptides [19], and DNA vaccines [20]. In each case only transient low-level effects were seen
on T-cell induction or HCV viral load. More recently repeated vaccination in HCV infected patients
with MVA encoding HCV non-structural proteins in combination with pegylated interferon-α and
ribavirin (PEG-IFNα/rib) was associated with the induction of HCV-specific T-cells at low levels
with a non-significant increase in SVR rates in the vaccinated arm [21,22]. However, studies of HCV
immunotherapy have often not evaluated the effect of vaccination in the context of the circulating
viral sequence.
We have recently developed a T-cell vaccine for HCV, employing a chimpanzee-derived
adenovirus 3 (ChAd3) prime and a human adenovirus 6 (Ad6) encoding the non-structural region of
HCV (NSmut; genotype 1b) in a prime-boost regimen. Limitations of this regimen included a modest
effect of boost vaccination and poor induction of CD4+ HCV-specific T-cells in healthy volunteers [23],
and induction of low magnitude, narrowly-targeted, HCV-specific T-cell response in HCV infected
patients [24].
We have since optimised this vaccine regimen in healthy volunteers by employing an MVA-NSmut
boost vaccination, which induces high-magnitude polyfunctional CD4+ and CD8+ T-cells, targeting
multiple HCV antigens in healthy volunteers [25]. Here, we test whether this optimised regimen is
safe and immunogenic in HCV infected patients. An important comparison is made between the
immunogencity of this vaccine regimen in healthy volunteers [25] vs. HCV infected patients. We also
assess whether the ChAd3-NSmut/MVA-NSmut vaccine regimen can safely induce a more balanced
CD4+ and CD8+ T-cell response, of enhanced breadth, magnitude, and functionality compared to a
ChAd3-NSmut/Ad6-NSmut vaccine regimen in HCV infected patients, as it does in healthy volunteers.
In a mouse model of persistent viral infection (lymphocytic choriomeningitis virus (LCMV))
T-cell induction by vaccination was reduced in the presence of high viral loads [26,27]. We, therefore,
assessed vaccine immunogenicity in patients with either high (untreated), intermediate, or low viral
loads (after lead-in of PEG-IFNα/rib before vaccination) to determine the impact of viral load on
vaccine immunogenicity. Since HCV may undergo mutation and rapidly escape T-cell immunity, it is
essential to assess whether T-cells induced by vaccination effectively recognise a patient’s autologous
viral sequence. We use full-length viral sequencing and epitope mapping to evaluate the interaction
between T-cell induction and viral sequences at key antigenic targets.
2. Materials and Methods
2.1. Patient Enrolment and Study Arms
Patients aged 18–65 with HCV genotype-1 were eligible for inclusion. Patients with HIV, HBV,
immunosuppressive illness, or evidence of cirrhosis (clinical, biochemical, or histological) were
excluded (patient demographics; Table 1). Patients were recruited at Oxford University NHS Trust.
The study (EudraCT: 2009-018260-10) was approved by the Medicines and Healthcare products
Regulatory Agency (MHRA), and registered in the ClinicalTrial.gov database (ID: NCT01296451).
All volunteers gave written informed consent before enrolment, and the studies were conducted
according to the principles of the Declaration of Helsinki and in accordance with good clinical practice.
Study arms and vaccination regimes are detailed (Supplementary Materials Table S1).
Fifteen volunteers were screened and 13 enrolled into arms A and B, receiving concurrent
PEG-IFNα/rib therapy (48 weeks), or arm C, receiving vaccine alone. Patients received 2.5 ˆ 1010 viral
particles (vp) ChAd3-NSmut prime and MVA-NSmut 2 ˆ 108 PFU eight weeks later. A dose escalation
for ChAd3-NSmut is described in [24]. The MVA dose was selected on the basis of the use of MVA
vectors in human studies [25,28,29]. One patient (356) received both ChAd3-NSmut and MVA-NSmut
vaccinations but withdrew shortly after boost vaccination and, therefore, data from this patient is
only included in Table 1. Fourteen weeks after starting PEG-IFNα/rib all patients in arm A had
a >2 log drop in viral load before vaccination. Arm B received 2.5 ˆ 1010 vp two weeks after starting
PEG-IFNα/rib. Vaccines were administered intramuscularly.
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Table 1. Demographics of HCV infected patients enrolled in HCV003 trial.
Regimen Patient Arm Age(years) Sex
HCV
Genotype
Baseline Viral
Load (IU/mL) HLA-A HLA-B HLA-C HLA-DR HLA-DQ RVR EVR SVR
14wk
IFNa/Rib
lead-in
pre-vaccination
357 A 58 M 1a 33.7 ˆ 106 02/30 13/62 06/10 04/07 02/08 No No No
362 A 43 M 1a 32,000 01/29 08/44 07/16 01/07/53 02/05 Yes Yes No
364 A 46 F 1a 109,382 03/24 7 07/16 01/103 05 Yes Yes No
366 A 36 F 1a 2.0 ˆ 106 02/33 07/65 07/08 11/103 05/07 Yes Yes Yes
2 weeks
IFNa/Rib
lead-in
pre-vaccination
350 B 56 M 1a 1.8 ˆ 106 24/26 35/51 04/15 04/09 08/09 Yes Yes No
351 B 38 M 1b 2.7 ˆ 106 02 36/50 06/10 - - Yes Yes Yes
352 B 52 M 1b 9.4 ˆ 106 03/24 07 07 01/15/51 05/06 No Yes No
354 B 51 M 1a 3.2 ˆ 106 01/02 08/62 07/09 52/53 02/08 No No No
356 B 38 M 1b 173,764 11/66 35/41 04/17 13 06 Yes Yes w/d
Vaccinated
treatment-naïve
355 C 59 M 1a 467,000 02/03 27/65 02/08 52/53 06/07 n/a n/a n/a
358 C 49 F 1a 42,000 03/68 44/60 10/16 07/13/52/53 02/06 n/a n/a n/a
359 C 35 M 1a 237,000 01/66 08/41 07/17 52/53 02 n/a n/a n/a
360 C 51 F 1a 21.7 ˆ 106 02/24 35/44 07/09 04/11/52/53 07 n/a n/a n/a
M = male. F = female. RVR= rapid virological response (viral load <50 IU/mL at wk 4 of treatment). EVR = early virological response (viral load undetectable at week 12 of treatment).
SVR = sustained virological response, “yes” indicates undetectable viral load 6 months after the end of treatment. n/a = not applicable w/d = withdrawn from study.
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ChAd3-NSmut/MVA-NSmut vaccination of healthy volunteers [25] is a separate arm of the same
clinical trial as the HCV infected patients described here; this trial is registered as ID: NCT01296451
in the ClinicalTrial.gov database. Comparisons are also made with previously published vaccine
studies employing ChAd3-NSmut/Ad6-NSmut in HCV infected patients (HCV002) registered as
ID: NCT01094873 [24].
2.2. Vaccine Constructs
The chimpanzee adenovirus 3 (ChAd3) vector encoding NS3-5B (1985 amino-acids) of genotype-1b
BK strain HCV (accession number M58335) has been described previously [30,31] and was
manufactured at the Clinical BioManufacturing Facility, Oxford University. A modified vaccinia
Ankara construct containing the same transgene as described above has been previously described [25].
2.3. Peptides and Antigens
Four hundred ninety-four peptides, 15 amino-acids long, overlapping by 11 amino-acids (BEI
Resources, Manassas, VA, USA), were divided into six pools (F–M) corresponding to NS3p, NS3h, NS4,
NS5A, NS5B I, and NS5B II (mean 82, range 73–112 peptides/pool) matching HCV genotype 1B strain
BK. For cross-reactivity assays peptides were synthesised by ProImmune, Oxford. PepTivatorAdV5
Hexon pool was supplied by Miltenyi Biotec (Cologne, Germany). Peptides were used at 3 µg/mL
and 1 µg/mL for ELISpots and ICS, respectively.
2.4. IFNγ-ELISpot Assays
IFNγ-ELISpot assays were performed ex vivo in triplicate at 2ˆ 105 peripheral blood mononuclear
cells (PBMC)/well. PBMC were separated via density gradient and counted using a Guava Personal
Cell Analyser (Merck Millipore, Darmstadt, Germany). Internal controls were DMSO and R10 (negative
controls) and Concavalin A, FEC (HLA class I-restricted peptides from influenza, Epstein-Barr virus,
and CMV), and CMV lysate (Virusys Corporation, Taneytown, MD, USA).
A positive cut off for HCV-specific T-cell responses in the IFNγ-ELISpot assay was defined
in both HCV infected patients [24] and healthy volunteers [25] separately using: (i) mean + 3 ˆ
standard-deviation of SFC/106 PBMC in negative control wells, giving ě39 SFC/106 PBMC/pool in
HCV infected patients and ě48 SFC/106 PBMC/pool in healthy volunteers; (ii) and ě three times
background (mean SFC/106 PBMC in DMSO well); and (iii) positivity in response to vaccination in
HCV patients was also defined as a >30% increase in pre-existing responses, or the induction of T-cells
targeting new antigens.
Positive pools were summed and the background subtracted. Epitope specificities were
determined using frozen PBMC rested overnight, by dividing positive peptide pools into minipools
of approximately 10 peptides, then mapping to 15 amino acid long peptides and optimal length
peptides. CD8+ T-cell depletion IFNγ-ELISpots were performed using individual peptides and
negative depletion beads (Dynal magnets).
2.5. Intracellular Cytokine Staining
PBMC at 1 ˆ 106 cells/100 µL were stimulated with peptide pools (F + G + H = NS3/4, I + L + M
= NS5A/B) or PMA (phorbol 12-myristate 13-acetate)/ionomycin (50 and 500 ng/mL respectively), or
unstimulated (DMSO; 5 ng/mL). Brefeldin-A was added (10 µg/mL) 1 h later, cells incubated overnight
(37 ˝C), stained with fixable-NIR live/dead dye (Life Technologies, Carlsbad, CA, USA), fixed and
permeabilised (Foxp3 Fix/Perm kit, BD Biosciences, San Jose, CA, USA), then stained with CD3-Pacific
Orange, CD4-Qdot605, CD8-peridinin chlorophyll protein (perCp) Cy5.5, IFNγ-AlexaFluor700 (1:50),
IL2-APC (allophycocyanin), TNFα-PE (phycoerythrin)-Cy7, IL17-PE in perm-buffer (30 min room
temperature (RT)). All flow cytometry was performed on a BD LSRII machine and analysed using
FlowJo v9.5.2 (Treestar, Ashland, OR, USA).
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2.6. Thymidine Incorporation Proliferation Assay
Thymidine incorporation assays were performed ex vivo as previously described [23], on fresh
PBMC, 2 ˆ 105 PBMC/well (in triplicate) with HCV proteins (1 µg/mL; Mikrogen GMBh, Neuried,
Germany) and [3H] thymidine incorporation. A stimulation index (SI) ě 3 was considered positive.
2.7. HLA Class I Pentamer Staining
Frozen PBMC were thawed and stained ex vivo with HLA*0201 or HLA*0101 PE-labelled
pentamers (Proimmune, Oxford, UK; 20 min in PBS, RT), stained with LIVE/DEAD Fixable Near-IR
Dead Cell Stain Kit (Thermo Fisher, Carlsbad, CA, USA; 20 min RT), fixed (1% formaldehyde in
PBS, 20min RT), then stained with: CD3-Pacific-Orange, CD8-Pacific-Blue, and either stained with
CCR7-PeCy7, CD45RA-FITC, CD38-PerCP5.5; or PD-1-PeCy7, Tim3-AlexaFluor700, CTLA-4-APC,
2B4-PerCpCy5.5 for 30 min RT; or permeabilised (10ˆ permeabilisation buffer; ebiosciences, San Diego,
CA, USA) and stained with PD1-PeCy7, Perforin-FITC, Granzyme B-AlexaFluor700 30 min RT.
For intranuclear staining, PBMC were stained as above for pentramers and Live/Dead dye, and
then surface stained with: CD3-Pacific-orange, CD8-AlexaFluor700, CD45RA-BV421, CCR7-Pe-Cy7
(30 min RT). PBMC were then fixed (1 h RT) and permeabilised using the Foxp3/Transcription Factor
Staining Buffer Set (ebiosciences; 45 min RT) and stained with eomes-eFluor660 and Tbet-BV605.
2.8. HCV RNA Quantification
HCV RNA levels (lower limit of quantification 15 IU/mL) and subtype were determined at the
virology laboratory, John Radcliffe Hospital, Oxford (COBAS AMPLICOR HCV test v2).
2.9. HCV Viral Sequencing
Autologous virus was sequenced at baseline and viral relapse. Thawed plasma (500 µL) was
pelleted by centrifugation (23,600ˆ g at 4 ˝C for 60 min) and resuspended in 140 µL of plasma. Viral
RNA was extracted using a QIAmp Viral RNA mini kit (Qiagen, Hilden, Germany).
For Sanger sequencing RNA was reverse transcribed and first-round PCR was performed
using Superscript III One-Step RT-PCR (Invitrogen, Carlsbad, CA, USA) with specific primers and
PCR cycling conditions [24]. Second-round PCR used High Fidelity Taq DNA polymerase (Roche,
Burgess Hill, UK). PCR products were gel or PCR purified (Qiagen). Products were sequenced
bidirectionally using second-round internal primers and Prism Big Dye (Applied Biosystems) on an
ABI 3100 automated sequencer. Cycling conditions were: 96 ˝C ˆ 1 min, followed by 30 cycles
of 96 ˝C ˆ 15 s, 50 ˝C ˆ 10 s, 60 ˝C ˆ 4 min. Sequences were analysed and aligned using
Sequencher (Version 4.10.1, Gene Codes Corporation, Ann Arbor, MI, USA) and Se-AI (Version
2.0 a11, http://tree.bio.ed.ac.uk/software/).
Libraries were prepared for Illumina full-length viral sequencing using the NEBNext® Ultra™
Directional RNA Library Prep Kit for Illumina® (New England Biolabs, Ipswich, MA, USA) with 5 µL
sample (maximum 10 ng total RNA) and previously published modifications of the manufacturer’s
guidelines (Version 2.0) [32], briefly: fragmentation for 5 or 12 min at 94 ˝C, omission of Actinomycin
D at first-strand reverse transcription, library amplification for 15–18 PCR cycles using custom
indexed primers [33] and post-PCR clean-up with 0.85ˆ volume Ampure XP (Beckman Coulter,
High Wycombe, UK).
Libraries were quantified using Quant-iT™ PicoGreen® dsDNA Assay Kit (Invitrogen) and
analysed using Agilent TapeStation with a D1K High Sensitivity kit (Agilent, Santa Clara, CA, USA)
for equimolar pooling, then re-normalized by qPCR using the KAPA SYBR® FAST qPCR Kit (Kapa
Biosystems, Wilmington, MA, USA) for sequencing. Metagenomic virus RNA-Seq libraries were
sequenced with 100 base-paired end reads on the Illumina HiSeq 2500 with v3 Rapid chemistry
(San Diego, CA, USA).
De-multiplexed sequence read-pairs were trimmed of low-quality bases using QUASR v7.01 [34]
and adapter sequences with CutAdapt Version 1.7.1 [35] and subsequently discarded if either read had
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less than 50b remaining sequence or if both reads matched the human reference sequence using Bowtie
Version 2.2.4 [36]. The remaining read pool was screened against a BLASTn database containing
all 165 HCV genomes [37] covering its diversity both to choose an appropriate reference and to
select those reads which formed a majority population for de novo assembly with Vicuna v1.3 [38]
and finishing with V-FAT v1.0 (http://www.broadinstitute.org/scientific-community/science/
projects/viral-genomics/v-fat). Reads were mapped back to the assembly using Mosaik v2.2.28 [39],
variants were called by V-Phaser v2.0 [40], and intra-host diversity was explored with V-Profiler
v1.0 [41].
2.10. Sequence Variability at T-cell Epitopes at a Population Level
HCV sequences were downloaded from the Los Alamos database (http://hcv.lanl.gov/content/
index). Incomplete sequences and non-genotype 1a or 1b sequences were excluded.
2.11. nAbs to ChAd3 Vector
An assay measuring the neutralising antibodies against ChAd3 vector were performed as
previously described using recombinant adenoviruses expressing the reporter geneSEAP [42].
2.12. Statistical Analysis
Data was assumed to have a non-Gaussian distribution. Non-parametric tests were used
throughout; paired tests within an individual (Wilcoxon matched-pairs signed rank test) or unpaired
tests between individuals (Mann-Whitney). For correlations, Spearman’s r test was used. Two-tailed
p-values were used throughout. A p value < 0.05 was considered significant. Prism v. 5.0d for Mac was
used for analysis. * = p ď 0.05; ** = p ď 0.01; *** = p ď 0.001; **** = p < 0.0001.
3. Results
3.1. Patient Characteristics and Virological Outcome
Patients infected with genotype 1 HCV were vaccinated with ChAd3-NSmut after 14 (arm A) or
two (arm B) weeks lead-in of PEG-IFNα/rib treatment, or without treatment (arm C), and all were
boosted with MVA-NSmut eight weeks after prime vaccination (Supplementary Materials Table S1).
All vaccinated HCV infected patients were Caucasian, nine of 13 were male, median age 49
(range 35–59) years, mean baseline alanine transaminase (ALT) 67 (range 21–295) IU/mL, and median
baseline HCV RNA 1.8 ˆ 106 (range 32,000–33.7 ˆ 106) IU/mL (Table 1). Of the patients treated with
PEG-IFNα/rib, 25% achieved sustained virological response (SVR; undetectable HCV RNA six months
post-completion of treatment) and one was lost to follow-up. One patient (354) ceased PEG-IFN/rib
due to a failure to achieve an early virological response (HCV RNA undetectable after 12 weeks of
treatment (EVR) but continued to give blood for immunological assessment. Another patient (356)
recommenced intravenous drug use two weeks after receiving boost vaccination and withdrew consent
for ongoing trial participation.
3.2. Vaccination with ChAd3-NSmut and MVA-NSmut Is Well Tolerated
No serious adverse reactions (ARs) occurred during the course of the study (Supplementary
Materials Figure S1A). All localised ARs relating to ChAd3-NSmut vaccination were of mild severity,
with local pain occurring in 25% of vaccinees and few systemic ARs being observed, with the most
common being myalgia, malaise, and headache in 16.67% of vaccinees.
Local ARs were more common following MVA-NSmut boost vaccination, with local pain occurring
in 50% of subjects (median duration 3.4 days; Supplementary Materials Figure S1A). Two patients
recorded systemic ARs of moderate severity (syncope and headache), while all other ARs were mild.
No significant change in liver biochemistry (ALT) was observed after vaccination. For patient 357, a
transient flare in ALT (peak 129 IU/mL) 2.5 months after boost vaccination was attributed to increased
alcohol consumption (Supplementary Materials Figure S1B).
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3.3. Pre-Existing HCV-Specific T-Cell Responses
Three of the 12 patients enrolled in the trial had detectable pre-existing T-cell responses to the
non-structural proteins of HCV (351, 352, 358; Figure 1E,G,K, respectively). Where possible, these
responses were mapped to individual 15mer peptides, identifying five epitope targets (Table 2).
An epitope prediction programme was used to identify potential optimal sequences within each
15mer (Syfpethi), but these were not tested in vitro due to a lack of available PBMC. Of the five
peptides identified, only one contained a previously described epitope (AYAAQGYKVL [43]; Table 2),
however, this had been shown to be restricted to HLA-Cw*03, which is not present in patient 358.
Another peptide contained the HLA-A2 restricted epitope (QLDLSGWFV), described in a paper
investigating the rational design of vaccine immunogens using epitope prediction [44], however, when
tested in vitro, this optimal peptide did not stimulate a response in patient 351.
Vaccines 2016, 4, 27 8 of 28 
3.3. Pre-Existing HCV-Specific T-Cell Responses 
Three of the 12 patients enrolled in the trial had detectable pre-existing T-cell responses to the 
non-structural proteins of HCV (351, 352, 358; Figure 1E,G,K, respectively). Where possible, these 
responses were mapped to individual 15mer peptides, identifying five epitope targets (Table 2). An 
epitope prediction programme was used to identify potential optimal sequences within each 15mer 
(Syfpethi), but these were not tested in vitro due to a lack of available PBMC. Of the five peptides 
identified, only one contained a previously described epitope (AYAAQGYKVL [43]; Table 2), 
however, this had been shown to be restricted to HLA-Cw*03, which is not present in patient 358. 
Another peptide contained the HLA-A2 restricted epitope (QLDLSGWFV), described in a paper 
investigating the rational design of vaccine immunogens using epitope prediction [44], however, 
when tested in vitro, this optimal peptide did not s imulate a response in patient 351.  
 
Figure 1. Magnitude of T-cell response targeting HCV NS in ChAd3-NSmut/MVA-NSmut-vaccinated 
HCV infected patients: the total ex vivo IFNγ ELISpot response to the non-structural region of HCV 
(NS) encoded in the vaccine, split by peptide pool, is shown across the clinical trial for individual 
patients after ChAd3-NSmut prime and MVA-NSmut boost vaccination. Positive responses (≥39 
SFC/106 peripheral blood mononuclear cells [PBMC]) to a peptide pool are coloured. S = Screen. 
Vaccinations are indicated by dashed lines. (A–D) Patients in arm A received 14 weeks of PEG-
IFNα/rib treatment (48 weeks total) before vaccination; (E–H) Patients in arm B received two weeks 
of PEG-IFNα/rib treatment before vaccination; (I–L) Patients in arm C are vaccinated, treatment-
naïve, HCV infected patients. 
S 2 4  6 10 11 14 16 20 24 36 48 60 72
0
100
200
300
400
500
Weeks post commencing IFN/ribavirin therapy
Patient 351 
IF
N
g 
S
F
C
/1
0
6
P
B
M
C
MVAChAd3
S 2 4  6 10 11 14 16 20 24 36 48 60 72
0
100
200
300
400
500
Weeks post commencing IFN/ribavirin therapy
Patient 350 
IF
N
g 
S
F
C
/1
0
6
P
B
M
C
MVAChAd3
S 2 4  6 10 11 14 16 20 24 36 48 60 72
0
100
200
300
400
500 Patient 352
Weeks post commencing IFN/ribavirin therapy
IF
N
g 
S
F
C
/1
0
6
P
B
M
C
MVAChAd3
S 14 16 18 22 23 26 28 32 36 48 60 70
0
100
200
300
400
500
Weeks post commencing IFN/ribavirin therapy
Patient 357 
IF
N
g 
S
F
C
/1
0
6
P
B
M
C
MVAChAd3
S 14 16 18 22 23 26 28 36
0
100
200
300
400
500
IF
N
g 
S
F
C
/1
0
6
P
B
M
C
Weeks post commencing IFN/ribavirin therapy
Patient 362 
MVAChAd3
#
S 14 16 18 22 23 26 28 32 36 48 72
0
100
200
300
400
500
Weeks post commencing IFN/ribavirin therapy
Patient 366 
IF
N
g 
S
F
C
/1
0
6
P
B
M
C
MVAChAd3
##
S 0 2 4 8 9 12 14 18 22 34 46
0
500
1,000
1,500
1,500
2,000
IF
N
g 
S
F
C
/1
0
6
P
B
M
C
Patient 359MVAChAd3
#
Weeks after prime vaccination
S 0 2 4 8 9 12 14 18 22 34 46
0
500
1,000
1,500
1,500
2,000
IF
N
g 
S
F
C
/1
0
6
P
B
M
C
Patient 355
Weeks after prime vaccination
MVAChAd3
S 2 4  6 10 11 14 16 20 24 36 48 60 72
0
100
200
300
400
500
Weeks post commencing IFN/ribavirin therapy
Patient 354 
IF
N
g 
S
F
C
/1
0
6
P
B
M
C
MVAChAd3
#
S 14 16 18 22 23 26 28 32 48 60
0
100
200
300
400
500
Weeks post commencing IFN/ribavirin therapy
Patient 364 
IF
N
g 
S
F
C
/1
0
6
P
B
M
C
MVAChAd3
#
S 0 2 4 8 9 12 14 18 22 34 46
0
500
1,000
1,500
1,500
2,000
IF
N
g 
S
F
C
/1
0
6
P
B
M
C
MVAChAd3 Patient 358
Weeks after prime vaccination
S 0 2 4 8 9 12 14 18 22 34
0
100
200
300
400
500
IF
N
g 
S
F
C
/1
0
6
P
B
M
C
Patient 360
Weeks after prime vaccination
MVAChAd3
#
Treatment-naïve
(group C)
14wk Rib/IFN lead-in
(group A)
2wk Rib/IFN lead-in
(group B)
A
B
C
D
E
F
G
H
I
J
K
L
Figure 1. Magnitude of T-cell response targeting HCV NS in ChAd3-NSmut/MVA-NSmut-vaccinated
HCV infected patients: the total ex vivo IFNγ ELISpot response to the non-structural region of
HCV (NS) encoded in the vaccine, split by peptide pool, is shown across the clinical trial for
individual patients after ChAd3-NSmut prime and MVA-NSmut boost vaccination. Positive responses
(ě39 SFC/106 peripheral blood mononuclear cells [PBMC]) to a peptide pool are coloured. S = Screen.
Vaccinations are indicated by dashed lines. (A–D) Patients in arm A received 14 weeks of PEG-IFNα/rib
treatment (48 weeks total) before vaccination; (E–H) Patients in arm B received two weeks of
PEG-IFNα/rib treatment before vaccination; (I–L) Patients in arm C are vaccinated, treatment-naïve,
HCV infected patients.
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Table 2. Peptides to which T-cell IFNγ-ELISpot responses were detectable prior to vaccination.
15mer Peptide Amino AcidLocation
Responding
Patient Likely Epitope
Predicted
HLA-restriction
AYAAQGYKVLVLNPS NS3 1243–1252 358 AYAAQGYKVLˆ Cw03
LTTGSVVIVGRIILS NS4A 1677–1686 358 TGSVVIVGR* A68
TEVDGVRLHRYAPAC &
PEFFTEVDGVRLHRY NS5A 2124–2132 358 EVDGVRLHRY* A3/B44
LEFWESVFTGLTHID NS3 1555–1564 358 LEFWESVFTG* B44/B60
PASSQLDLSGWFVAG NS5B 2963–2971 351 QLDLSGWFV* A2
* most likely epitopes—-as predicted by epitope prediction program (www.syfpeithi.de; 9 or 10mer with highest
prediction score and appropriate HLA based on responding patients HLA-alleles)—-are highlighted in bold in
15mer sequences; ˆ previously reported epitope [43].
3.4. Heterologous ChAd3-NSmut Prime/MVA-NSmut Boost Vaccination Can Induce HCV-specific T-cell
Responses in Patients Chronically Infected with HCV, But at a Reduced Magnitude When Compared to
Healthy Volunteers
There is no clear pattern to the kinetics of the T-cell response to ChAd3-NSmut/MVA-NSmut
vaccination in HCV+ patients (Figure 2A–C), with some patients showing T-cell expansion after: both
prime and boost vaccination (patients 351, 366, 358, and 355); after MVA-NSmut boost only (patients
357, 360, and 364) or no novel detectable T-cell response to either vaccine (patients 350, 354, 352, 362).
Although the peak magnitude of the T-cell response is seen after MVA-NSmut boost in most patients it
varied from one week to six weeks post-vaccination, unlike in healthy volunteers where a peak one
week post-MVA-NSmut was consistently seen [25].
When all HCV infected patients are considered together there is no significant induction of
HCV-specific T-cells by prime (p = 0.2187) or boost vaccination (p = 0.2031; Figure 2A); however,
when considering responses to individual peptide pools covering the NS region of HCV, four of the
eight HCV infected patients receiving PEG-IFNα/Rib treatment (351, 357, 364, 366) had a detectable
vaccine-induced T-cell response (a new positive pool or >30% increase in the baseline response
to a peptide pool; Figure 2A,B; Table 3). The peak magnitude of the T-cell response is seen after
MVA-NSmut boost in most patients (1–6 weeks post vaccination). When compared to the magnitude of
the HCV-specific T-cell response induced in healthy volunteers receiving ChAd3-NSmut/MVA-NSmut,
the vaccine-induced T-cell responses were significantly lower in magnitude in HCV infected patients
(at prime p = 0.0003 ***, at boost p < 0.0001 ****; Figure 2A).
The relationship between HCV-specific T-cell induction and circulating viral load is best evaluated
in arm C, where patients do not have the confounding effect of PEG-IFNα/rib treatment. In this arm
4/4 patients responded to vaccination (Figure 1I–L; 355, 358, 359, 360), developing new or expanded
HCV-specific T-cell responses. However, this had no effect on their HCV RNA levels (Figure 2C).
We found no significant difference in T-cell response to vaccination in patients with high
(untreated), intermediate (two weeks lead-in of PEG-IFNα/rib), or low (14 weeks lead-in of
PEG-IFNα/rib pre-vaccination) viral load at the time of vaccination (Figure 2D). This was unexpected
as murine models of chronic viral infection with LCMV have shown that therapeutic vaccination is
more efficacious in mice with low viral loads [26,27].
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Ma n- Whitney t-test; (B) the kinetics of the response in individual HCV infected patients receiving
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kinetics of the response in individual CV infected patients receiving 3- S t MVA-NSmut
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and (D) a comparison of the peak response after ChAd3-NSmut prime and after MVA-NSmut b ost
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loads at the time of vaccination. Bar at median (p > .05 Kruskal-Wallis multiple comparisons ANOVA
for prime, and for b ost).
Vaccines 2016, 4, 27 11 of 28
Table 3. T-cell responses mapped to individual peptides/pools.
Regimen Group Patient HLA-A HLA-B HLA-C pre-vaccination+ve pools
post vaccination+ve
pools Mapped to peptide (parent pool)
14wk IFNa/Rib lead-in
pre-vaccination A
357 02/30 13/62 06/10 - G KLSGLGINAV (G)
362 01/29 08/44 07/16 - - -
364 03/24 07 07/16 - F, I, M -
366 02/33 07/65 07/08 - F, G KLSGLGINAV (G)
2 weeks IFNa/Rib lead-in
pre-vaccination B
350 24/26 35/51 04/15 - - -
351 02 36/50 06/10 M G, M KLSGLGINAV (G), PASSQLDLSGWFVAG (M)
352 03/24 07 07 G, H, I, L G, H, I -
354 01/02 08/62 07/09 - - -
Vaccinated
treatment-naïve
C
355 02/03 27/65 02/08 - G, M KLSGLGINAV (G), SRARPRWFM (M)
358 03/68 44/60 10/16 F, G, H, I, L, M F, G, H, I, L, M AYAAQGYKVLVLNPS (F), LEFWESVFTGLTHID (G),LTTGSVVIVGRIILS (H), TEVDGVRLHRYAPAC (I)
359 01/66 08/41 07/17 - F, G, I HSKKKCDEL (G)
360 02/24 35/44 07/09 - G KLSGLGINAV (G)
T-cell responses to a peptide pool that are only detectable after vaccination are highlighted in red. Responses that were mapped to the epitope or peptide level are shown. If the
optimal has been predicted in silico but not tested ex vivo the predicted optimal is shown in bold within the sequence of the 15mer peptide.
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3.5. ChAd3/Ad6 vs. ChAd3/MVA Vaccine Regimens in HCV Infected Patients
In healthy volunteers MVA-NSmut has shown a greater capacity to boost ChAd3-NSmut
primed HCV-specific T-cells, to broaden the T-cell response, and to improve the functionality of
the induced HCV-specific T-cells when compared to Ad6-NSmut as a boosting vector [25]. Next we
compare the immunogenicity of MVA-NSmut vs. Ad6-NSmut as boosting vectors in HCV infected
patients. There was no significant difference in magnitude of the peak (any time after prime
vaccination) or memory (measured at the end of the study, 26 weeks after boost vaccination) HCV
NS-specific T-cell response in HCV infected patients who received Ad6-NSmut vs. MVA-NSmut
boost vaccination, regardless of whether patients received concomitant PEG-IFN-α/rib treatment
(Figure 3A). PEG-IFN/rib treatment and concomitant reduction in HCV RNA in itself does not appear
to enhanced T-cell responses, however, as only T-cell responses targeting regions of HCV contained
within the vaccine immunogen (non-structural region NS3-NS5b) were expanded post-vaccination
and the T-cell response targeting the structural regions (Core, E1, E2, p7 and NS2) were unchanged
throughout the trial in all patients (Figure 3B; [45]).
The number of positive peptide pools at the peak of the T-cell response was significantly reduced
in HCV infected patients relative to healthy controls, and patients who received MVA-NSmut did not
have a broader response than those who received Ad6-NSmut boost vaccination (p = 0.182; Figure 3C).
Therefore, the use of an highly immunogenic vaccine regimen, optimised in healthy volunteers, failed
to reconstitute a strong HCV-specific T-cell response in HCV infected patients.
3.6. The Relationship between Vaccine Induced T-cell Specificity and Endogenous Viral Sequence
Where possible vaccine-induced T-cell responses to HCV peptide pools were mapped to
individual 15mers and optimal peptides; three optimal epitope sequences were identified, all of
which had been previously identified in natural infection [44,46,47] or in vaccination in healthy
volunteers [23,25] (Figure 4). No CD4+ T-cell responses were identified by peptide mapping.
The viral sequence variability at key epitopes targeted by vaccine-induced HCV-specific T-cells
was assessed using the Los Alamos database of HCV sequencing data. The relative frequency of viral
variants for genotype 1a and 1b HCV sequences at the epitopes NS31406 (KLSGLGINAV), NS5B2984
(SRARPRWFM), and NS31395 (HSKKKCDEL) are shown in Figure 4A–C. The most immunogenic
epitope (5/6 HLA-A2+ patients showing a response to this epitope), NS31406, was highly variable with
no single epitope being present in more than 50% of genotype 1a and 1b sequences. However, NS31395
was highly conserved, with 87.3% of all natural viral sequences (genotype 1a and 1b combined) and
the vaccine sequence being identical.
One explanation for why the induction of HCV-specific T-cells in untreated patients (without the
confounding immunomodulatory effects of PEG-IFN-α/rib) had no effect on HCV RNA is a lack of
cross-recognition of viral peptides presented on infected cells. We, therefore, performed full-length
viral sequencing and assessed the circulating viral sequence at key epitope targets. We confirmed the
clinical viral subtyping by producing a phylogenetic tree including patients’ sequences and reference
sequencing for HCV subtypes 1a, 1b, 2a, and 3a (Supplementary Materials Figure S2). Clustering
of individual patients’ viral sequences when measured at two different time points confirmed the
accuracy of full-length viral sequencing.
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In all instances where a T-cell response was detected after vaccination the patient’s autologous
virus had between one and three amino acid substitutions within the epitope from the vaccine
immunogen sequence (Table 4). For instance, the viral sequence in the only patient to make a T-cell
response to the HLA-B8 restricted NS31395 epitope was a rare variant (2.1% of sequences in the
los Alamos database) HSKRKCDEL; in all other patients the viral sequence was identical to the
vaccine immunogen, including two HLA-B8+ patients who had no detectable T-cell response to this
epitope. The HSKRKCDEL variant sequence was poorly recognised by ChAd3-NSmut/Ad6-NSmut
induced T-cells (Figure 4A). A vaccine induced T-cell response to NS31406 was detected in five
of the six HLA-A2+ patients, all of which had circulating virus with 2 or more amino acids that
differed from the vaccine sequence at this epitope. Importantly, when we tested the recognition of
peptides corresponding to the patient viral sequence there was limited or no cross-recognition by
vaccine-induced T-cells (Figure 4A–C). No change in viral sequence accompanied an induction of
HCV-specific T-cells after vaccination at these three antigenic targets (Table 4), which again suggests
vaccination is priming or boosting T-cells which have already been escaped by a patients autologous
virus. HCV-specific T-cells were only induced by vaccination when there was mismatch between
the patient virus and the vaccine immunogen and T-cell induction did not lead to a change in the
dominant viral sequence at epitope targets or reduce viral load.
A global defect in T-cell induction was not seen in HCV infected patients as T-cells targeting the
hexon of ChAd3 were expanded in all patients (Supplementary Materials Figure S3A). The limited
immunogenicity of ChAd3-NSmut in HCV infected patients relative to healthy volunteers cannot be
explained by a higher baseline titer of pre-existing neutralising antibodies to ChAd3 as baseline
titers were comparable between patients and volunteers (Supplementary Materials Figure S3B).
The induction of anti-ChAd3 nAb was also comparable, showing there is also no global defect in the
B-cell compartment in patients chronically infected with HCV (Supplementary Materials Figure S3B).
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Table 4. IFNγ ELISpot T-cell responses at baseline, circulating virus sequence vs. vaccine insert. A) HLA-B8 epitope, B) HLA-A2 epitope, C) Epitope of unknown
HLA restriction.
(A) Patient H S K K K C D E L (B) Patient K L S G L G I N A V (C) Patient S R A R P R W F M
HLA-B8
+ ve
pts
359 - - - R - - - - -
HLA-A2
+ve
pts
357 - - V A - - V - - - 357 - - - - - - - - W
359pv - - - R - - - - - 351 - - - A - - L - - - 351 - - - - - - - - -
354 - - - - - - - - - 354 - - T A M - - - - - 354 - H - - - - - - W
362 - - - - - - - - - 355 - - V A - - V - - - 355 - - - - - - - - W
HLA-B8
neg pts
357 - - - - - - - - - 355pv - - V A - - V - - - 355pv - - - - - - - - W
350 - - - - - - - - - 360 - - V A - - - - - - 360 - - - - - - - - W
351 - - - - - - - - - 360pv - - V A - - - - - - 360pv - - - - - - - - W
352 - - - - - - - - - 366 - - V S - - - - - - 366 - H - - - - - - W
356 - - - - - - - - -
HLA-A2
Neg
pts
350 - - V A - - - - - - 350 - - - - - - - - W
355 - - - - - - - - - 352 - - V A - - V - - - 352 - - - - - - - - W
355pv - - - - - - - - - 356 - - - - - - L - - - 356 - - - - - - - I -
358 - - - - - - - - - 358 - - V A - - V - - - 358 - - - - - - - - W
358 pv - - - - - - - - - 358pv - - V A - - V - - - 358pv - - - - - - - - W
360 - - - - - - - - - 359 - - V A - - V - - - 359 - - - - - - - - W
360pv - - - - - - - - - 359 - - V A - - V - - - 359pv - - - - - - - - W
364 n.d 364 n.d 364 n.d
366 - - - - - - - - - 362 - - V A - - - - - - 362 - - - - - - - L W
Viral sequence was determined at baseline and 2 weeks post-vaccination (pv; untreated patients only). The HCV vaccine immunogen sequence is given in the top line of each table.
A dashed line below indicates that an amino acid is identical to that in the vaccine immunogen. The epitopes to which individual patients have made a T-cell response (as measured by
ex vivo IFNγ-ELISpot assay) are shown in bold red font.
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3.7. Vaccine-Induced T-Cell Function and Phenotype in Patients with Chronic HCV
Next, we used intracellular cytokine staining (ICS) and the thymidine proliferation assays to
confirm the limited induction of functional HCV-specific T-cells seen by IFNγ ELISpot assay, to assess
specifically, CD4+ T-cell induction and the presence of T-cells with the capacity to proliferate or produce
IL-2 and TNFα. Cytokine producing HCV-specific T-cell populations were low in magnitude and
MVA-NSmut failed to boost a stronger CD4+ or CD8+ T-cell response relative to Ad6-NSmut boost
(Figure 5A). This is in stark contrast to what was seen in healthy volunteers, where MVA-NSmut boost
vaccination induced a significantly higher magnitude population of HCV-specific cytokine-producing
T-cells, in particular CD4+ T-cells [25]. MVA-NSmut boost vaccination of HCV infected patients
failed to induce HCV-specific T-cells that proliferate on stimulation with recombinant HCV proteins
(Figure 5B; data shown for stimulation of PBMC six weeks post MVA-NSmut boost; PBMC taken
24–26 weeks post (n = 3) and 40–62 weeks post (n = 7) MVA-NSmut also showed a stimulation
index <7 for all proteins in all patients tested).
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Figure 5. Functional analysis of vaccine-induced HCV-specific T-cells in HCV infected patients: (A) 
cytokine production by PBMC stimulated with peptide pools covering NS3-NS5b. The percentage of 
total CD4+ or CD8+ cells making IFNγ, TNFα, or IL-2 at the peak post-prime vaccination (2–8 weeks 
post-ChAd3-NSmut; open symbols), post-Ad6-NSmut boost (2–4 weeks post-Ad6-NSmut; black), or 
post-MVA-NSmut boost vaccination in HCV infected patients (1 week post-MVA-NSmut red). ICS 
was performed on patients with an IFNγ ELISpot response >150 SFC/106 PBMC where PBMC were 
available (ChAd3-NSmut/Ad6-NSmut vaccinees: 024 and 027, and 039; 103 post boost only; ChAd3-
NSmut/MVA-NSmut vaccinees: 355, 358, 351, and 352; 360 post-boost only). All values are after 
background subtraction (DMSO wells). Bars at median; and (B) proliferative capacity: the 
proliferative response to recombinant HCV proteins in patients six weeks post-MVA-NS boost, 
plotted as Stimulation Index (SI). SI ≥ 3 was considered positive. Responses to positive control 
antigens (concanavilin A and CMV lysate) are shown (crosses). Bars represent median values. 
The phenotype of HCV NS-specific T-cells at the peak of the response post MVA-NSmut boost 
was assessed in patients 355, 360, and 357 to investigate whether mismatched T-cells induced by 
vaccination in HCV infected patients are phenotypically similar to those induced in healthy 
volunteers. A subset of inhibitory coreceptors characteristic of exhausted HCV-specific T-cells (PD-1, 
Tim-3, CTLA-4 and 2B4 [48]) were also assessed on vaccine-induced T-cells. HCV NSmut-specific T-
cells expressed CD38 and perforin (Figure 6A) immediately after MVA-NSmut vaccination, similar 
to that seen in healthy volunteers; in all patients fewer pentamer+ cells expressed granzyme B and 
PD-1 after MVA-NSmut boost in HCV infected patients than in healthy controls. Pentamer+ T-cells 
in HCV infected patients did not express higher levels of inhibitory receptors than vaccine-induced 
HCV-specific T-cells in healthy volunteers long-term after vaccination (Figure 6B; example plots 
shown in Figure 6C).  
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Figure 5. Functional analysis of vaccine-induced HCV-specific T-cells in HCV infected patients:
(A) cytokine production by PBMC stimulated with peptide pools covering NS3-NS5b. The percentage
of total CD4+ or CD8+ cells making IFNγ, TNFα, or IL-2 at the peak post-prime vaccination (2–8 weeks
post-ChAd3-NSmut; open symbols), post-Ad6-NSmut boost (2–4 weeks post-Ad6-NSmut; black),
or post-MVA-NSmut boost vaccination in HCV infected patients (1 week post-MVA-NSmut red).
ICS was performed on patients with an IFNγ ELISpot response >150 SFC/106 PBMC where PBMC
were available (ChAd3-NSmut/Ad6-NSmut vaccinees: 024 and 027, and 039; 103 post boost only;
ChAd3-NSmut/MVA-NSmut vaccinees: 355, 358, 351, and 352; 360 post-boost only). All values
are after background subtraction (DMSO wells). Bars at median; and (B) proliferative capacity: the
proliferative response to recombinant HCV proteins in patients six weeks post-MVA-NS boost, plotted
as Stimulation Index (SI). SI ě 3 was considered positive. Responses to positive control antigens
(conca avili A and CMV lysate) are shown (crosses). Bars represent median values.
The phenotype of HCV NS-specific T-cells at the peak of the response post MVA-NSmut boost was
assessed in patients 355, 360, and 357 to investigate whether mismatched T-cells induced by vaccination
in HCV infected patients are phenotypically similar to those induced in healthy volunteers. A subset
of inhibitory coreceptors characteristic of exhausted HCV-specific T-cells (PD-1, Tim-3, CTLA-4 and
2B4 [48]) were also assessed on vaccine-induced T-cells. HCV NSmut-specific T-cells expressed CD38
and perforin (Figure 6A) immediately after MVA-NSmut vaccination, similar to that seen in healthy
volunteers; in all patients fewer pentamer+ cells expressed granzyme B and PD-1 after MVA-NSmut
boost in HCV infected patients than in healthy controls. Pentamer+ T-cells in HCV infected patients
did not express higher levels of inhibitory receptors than vaccine-induced HCV-specific T-cells in
healthy volunteers long-term after vaccination (Figure 6B; example plots shown in Figure 6C).
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Figure 6. Phenotype of vaccine-induced HCV-specific T-cells in patients vs. healthy volunteers:
(A–C) the percentage of pentamer+ cells (NS31436 ATDALMTY, NS31406 KLSGLGINAV) expressing
a given marker in HCV infected patients (red dots; 355, 357, 360) or healthy volunteers (black
stars) receiving ChAd3-NSmut/MVA-NSmut prime-boost vaccination. CD8+ CMV-specific T-cells
(pp65495–504) in healthy volunteers were also assessed. (A) Pentamer+ cells were stained ex vivo at
the time of peak magnitude of the T-cell response during the trial (as measured by IFNγ ELISpot;
2–4 weeks post ChAd3-NSmut; 1–6 weeks post MVA-NSmut) in HCV infected patients and healthy
volunteers. Bars represent median values. Kruskal-Wallis multiple comparison ANOVA with Dunn’s
correction and significant differences are illustrated; (B) inhibitory receptor staining of pentamer+
cells was performed at the end of the trial (20–62 weeks post MVA-NSmut prime) in HCV infected
patients (red dots) and healthy volunteers (black stars), or in C V+ healthy volunteers (pp65495–504
NLVPMVATV); and (C) example FACS plots of T-cell surface inhibitory marker staining, gated on total
CD8+ T-cells.
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Vaccine-induced CD8+ T-cells, show a partially dysfunctional phenotype when compared to
healthy volunteers, despite not cross-recognising a patient’s autologous viral sequence; in patients,
responses are skewed towards a Tem phenotype, but they lack the ability to produce antiviral cytokines,
to proliferate when exposed to cognate antigen, and often do not express the molecules indicative of
good cytolytic capacity.
To investigate whether the partially dysfunctional phenotype of vaccine-induced HCV-specific
T-cells is controlled at the level of transcription, we compared the expression of two transcription factors
(TFs) that control CD8+ T-cell memory development and effector functions (Tbet, T-box transcription
factor TBX21; eomes, eomesodermin) [49]. Bulk CD8+ T-cell memory subsets (CD45RA+CCR7+,
Naïve, Tn; CD45RA´CCR7+, Tcm; CD45RA´CCR7´, Tem; CD45RA+CCR7´, Temra) showed
distinct TF expression, with Tbet and eomes expression increasing progressively as one moves
from the Naïve-Tcm-Tem-Temra phenotype, both in HCV infected patients and healthy volunteers
(Figure 7A) [49]. Interestingly, Naïve CD8+ T-cells in HCV infected patients expressed higher levels
of Tbet, potentially indicating a bystander activation of this subset during chronic HCV infection,
as has been previously described [50]. The vaccine-induced HCV-specific memory T-cells that
persisted long-term after vaccination in HCV infected patients showed the characteristic Tbet/eomes
coexpression pattern seen by T-cells elicited by ChAd3/MVA prime-boost vaccination in healthy
volunteers, which closely mirrored the coexpression seen by CMV-specific T-cells (Figure 7B,C).
Despite having reduced effector function, vaccine-induced T-cells in HCV infected patients showed no
difference in expression of exhaustion marker or key TFs.
3.8. Culturing Pre-Vaccination HCV-Specific T-cells
One explanation for why vaccine-induced T-cells are not expanded to the same degree as in healthy
volunteers and why they are phenotypically different could be that HCV NS-specific T-cells have
already been primed during HCV infection in patients and that vaccination is boosting pre-existing,
exhausted T-cells rather than priming de novo responses. We identified 4 HLA-A2+ patients who
developed a detectable T-cell response after vaccination to NS31406 (but who showed no detectable
response pre-vaccination by ICS, pentamer or IFNγ ELISpot; 351, 355, 357, 360) and attempted to
expand T-cells to detectable levels from frozen pre-vaccination PBMC. Two of the four HCV infected
patients developed pentamer clouds to this epitope by day 19 of culture (all were negative at day 0,
day 12, and at all time points when cultured with DMSO; Figure 8). PBMC frozen pre-vaccination
from three healthy HLA-A2+ volunteers who responded to this epitope post-vaccination were also
cultured; as expected these volunteers did not develop pentamer clouds, showing our cell culture
method does not prime de novo responses [51].
In some instances the frequency of antigen-experienced HCV-specific T-cells circulating in HCV
infected patients before vaccination may be below the sensitivity limit of IFNγ ELISpot assay; therefore,
vaccination may be boosting pre-existing T-cells rather than inducing de novo responses. The absence
of cultured responses in all individuals who respond to vaccination could suggest some responses
are indeed primed by vaccination, however, it is also possible that our culture method is not sensitive
enough to expand all pre-primed responses from a small sample of pre-vaccination PBMC.
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Figure 7. Transcription factor expression by bulk CD8+ T-cells and by vaccine-induced HCV-specific
T-cells in patients vs. healthy volunteers: (A) the intranuclear expression of the transcription factors Tbet
(T-box transcription factor TBX21) and eEomes (eomesodermin) on T-cell memory subsets of bulk CD8+
T-cells (CD45RA+CCR7+, Tn; CD45RA´CCR7+, Tcm; CD45RA´CCR7´, Tem; CD45RA+CCR7´,
Temra) in HCV infected patients (red) and healthy volunteers (black). Bars represent median values;
(B) the percentage of pentamer+ cells (NS31406 KLSGLGINAV) co-expressing a given combination
of eomes and Tbet ex vivo in HCV infected patients (red; 355, 357, 366) or healthy volunteers (black
stars) at the end of the study after receiving ChAd3-NSmut/MVA-Nsmut prime-boost vaccination
(8–44 weeks post-MVA vaccination). CD8+ CMV-specific T-cells (pp65495–504) in healthy volunteers
were also assessed. Bars represent median values. Kruskal-Wallis multiple comparison ANOVA
with Dunn’s correction and significant differences are illustrated; and (C) example gating strategy for
intranuclear staining.
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4. iscussion
It is well established that, in chronic HCV infection, T-cells are found at a low magnitude and are
functionally attenuated, with reduced capacity to proliferate and to perform antiviral effector functions.
We sought to assess whether a potent T-cell vaccine could overcome these factors, either by enhancing
existing weak responses or by generating new HCV-specific T-cell responses. We have recently
shown that HCV-specific T-cells can be optimally induced in healthy volunteers by a prime-boost
vaccine regimen using a ChAd3-NSmut prime and a MVA-NSmut boost vaccination, overcoming the
limitations of previous heterologous ChAd3-NSmut/Ad6-NSmut regimen [25]. Here we assessed
the capacity of this potent regimen to restore anti-viral T-cell responses in patients with chronic HCV
infection and analysed in detail the complex interplay between HCV-specific T-cell induction and
circulating viral variants in the context of T-cell immunotherapy.
accination as well tolerated with no clear evidence of liver immunopathology.
Detectable HCV-specific T-cells responses are induced by ChAd3-NSmut/MVA-NSmut vaccination
in a subset of patients (4/8 PEG-IFN-α/rib treated and 4/4 untreated patients). However, an
important comparison with vaccination in healthy volunteers should be made: HCV-specific T-cell
induction by vaccination occurs in some, but not all HCV infected patients, whereas vaccination
induces HCV-specific T-cells in all healthy volunteers. Both the magnitude and the breadth of
the HCV-specific T-cell response after vaccination are significantly lower in HCV infected patients
than healthy volunteers. lthough MVA-NS ut is more immunogenic as a boosting vector than
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Ad6-NSmut in healthy volunteers, in HCV infected patients MVA-NSmut was no more immunogenic
than Ad6-NSmut. MVA-NSmut boost vaccination also does not broaden the T-cell response or induce a
significant population of HCV-specific CD4+ T-cells in HCV infected patients. In one untreated patient
(355) a T-cell response of comparable magnitude and kinetics with that seen in healthy volunteers was
observed, however, the response was narrowly targeted, dominated by monofunctional IFNγ CD8+
T-cells and had no effect on HCV RNA. The potency of our T-cell vaccines in healthy volunteers did
not predict their immunogenicity in a therapeutic setting.
Despite induction of HCV-specific T-cells in all patients not receiving PEG-IFN/rib, no change
in circulating viral load was observed, nor was any change driven by these T-cells in the dominant
viral sequence at the epitopes they targeted. Where T-cells were induced, they appeared partially
dysfunctional. In order to better understand why some patients responded to vaccination and others
did not, the sequence of endogenous virus in patients was evaluated. In vaccine responders there
was always sequence divergence between the circulating virus and vaccine immunogen at the epitope
targeted by vaccine-induced T-cells and, importantly, there was little or no cross-recognition of the viral
sequence by vaccine-induced T-cells in in vitro assays. Often, both responders and non-responders
shared the same variant sequence at an epitope pre-vaccination and no viral sequence was predictive
of a response to vaccination. Overall, HCV T-cell vaccines may induce T-cell responses in chronic
infection, but primarily in the absence of homologous antigen stimulation. The consequence of this
is that these T-cells are unlikely to limit viral replication or mediate viral eradication as they will not
recognise presented viral peptides on infected hepatocytes or antigen presenting cells. The finding that
vaccination had no effect on HCV viral load is in keeping with this. T-cells were not induced when
there was sequence homology between the vaccine immunogen and autologous virus at known T-cell
epitopes; in this context vaccination was unable to restore functional immunity.
Failure to respond to an epitope where the virus and vaccine have the same sequence may
be a result of T-cell exhaustion. Detection of T-cell responses where sequence mismatch occurred
may be the result of de novo priming, or expansion of memory responses. In a recent study on
chimpanzees, where DAA treatment was combined with therapeutic vaccination (Ad6/ChAd63/DNA
or Ad6/MVA/MVA/ChAd63 all encoding NSmut), vaccination failed to expand detectable CD4+
T-cell responses and despite initial viral control DAA-resistant HCV variants emerged, but were
not controlled by HCV-specific T-cells [52]. Most vaccine-induced T-cells targeted epitopes that
were not conserved in the circulating virus, and where the viral sequence was the same as the
vaccine immunogen and remained intact, intrahepatic T-cells were exhausted and failed to control
the virus [52]. A sustained multifunctional T-cell response against an intact epitope was observed in
the blood, however, localised exhaustion of T-cells targeting this epitope was seen in the liver [52];
therefore, even in the face of an un-escaped T-cell response, rapid exhaustion of T-cells by relatively low
level HCV replication and the tolerogenic liver environment can lead to the development of chronic
HCV infection.
We found no correlation between HCV viral load at the time of vaccination and the T-cell response
to vaccination. This was unexpected as evidence from murine models of chronic viral infection
suggest T-cell induction can be limited in the presence of high viral titers [26,27]. However, this
may be explained by the observation that PEG-IFNα and ribavirin have been shown to attenuate
cellular immune responses [45,53], or by the relatively small sample size. Of note, we found that
T-cells targeting the hexon of the Ad vectors were readily expanded on vaccination in patients
receiving PEG-IFNα, suggesting that therapy did not induce a global impairment of T-cell durability or
expansion. HCV infected patients showed a comparable nAb induction and seroconversion for
anti-ChAd3 nAbs, showing that there is no global defect in the B-cell compartment in patients
chronically infected with HCV. The recent licensing of IFN-free DAA regimens mean that the
immunomodulatory effects of PEG-IFNα/rib will no longer be an issue when testing therapeutic
vaccines as an adjunct to DAA therapy.
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T-cells generated by vaccination were functionally impaired in HCV infected patients compared
to healthy volunteers; they did not proliferate on stimulation with a cognate antigen, few produced
antiviral cytokines, and they often lacked markers of cytotoxic capacity, a phenotype that is
characteristic of chronic viral exposure [54,55]. A possible explanation for the partial dysfunction of
vaccine-induced T-cells is that HCV infection, per se, inhibits the effective priming of naive T-cells
to produce functional T-cell memory, however, here, patients generated robust anti-vector T-cell
responses. An alternative explanation is that vaccination is not priming truly naive T-cells, but is
stimulating memory responses that were generated early in infection. Historic infection with a virus
whose sequence matched the vaccine immunogen or the transient emergence of minor viral variants
within the swarm of quasi-species within a host that match the vaccine immunogen could prime T-cells
that no longer recognise circulating virus but that respond suboptimally to vaccination. The degree
of dysfunction could depend on the duration of antigen exposure at the epitope level—with more
functional responses associated with viral escape early in infection. In support of this, we found
pre-existing T-cell responses below the limit of detection that expanded on vaccination but failed to
recognise autologous viral sequences. These partially-dysfunctional vaccine-induced responses did
not however express significantly higher levels of inhibitory receptors (PD-1, 2B4, CTLA-4, Tim3) and
were not enriched for CD45RA re-expressing Temra phenotype T-cells, despite showing very little
proliferative capacity and polyfunctionality.
The transcription factor Tbet controls a programme of gene expression that confers cytolytic
potential and production of antiviral cytokines (in particular IFNγ) in CD8+ T-cells [56,57]. Another TF
with a somewhat overlapping role in controlling effector functions of T-cells, eomes appears
to be required for efficient memory development [58] but has also been associated with T-cell
exhaustion [56,59]. It may have been expected that the vaccine-induced HCV-specific T-cells would
express a lower level of Tbet and higher eomes expression, indicative of their partially dysfunctional
state, as has been shown for virus-specific T-cells in the setting of chronic viral infection [59,60];
however, no difference in the expression of TFs was seen between the vaccine-induced T-cells in HCV
infected patients and healthy volunteers, suggesting that these markers are not always indicative of
the ability of a T-cell to perform effector functions and alone cannot substitute the direct measurement
of cytokine production, proliferative and cytolytic capacity.
A lack of expansion of CD4+ T-cells by vaccination, even where there was sequence mismatch
between the immunogen and circulating virus, could indicate that rather than viral escape, other
mechanisms of immune evasion are used by HCV to avoid CD4+ T-cell recognition. In one study 75%
of CD8+ but only 18% of CD4+ T-cell epitopes showed amino acid changes during the development
of persistent HCV infection [61]. However, viral escape of the dominant CD4+ T-cell responses to
DNA/rVV vaccination in chimpanzees resulted in persistence of HCV after challenge [62].
It appears that delivery of an antigen to the periphery, away from the tolerogenic liver, in
the context of a highly-immunogenic non-replicative viral vectors is not enough to rejuvenate
T-cells that effectively recognise circulating HCV in chronically-infected patients. The targeting
of co-stimulatory [63,64] or inhibitory pathways [65] may be required to allow T-cells to respond to
vaccination and to re-acquire effector functions. In 2/3 HCV chronically-infected chimpanzees PD-1
blockade had no effect on viral load or T-cell responses [66]. One chimpanzee, who had a broader
T-cell response during initial infection, did respond to PD-1 blockade, with expansion and broadening
of both CD4+ and CD8+ T-cell responses coinciding with a significant drop in viral load, which
rebounded on withdrawal of the blockade. The continued assessment of inhibitory receptor blockade
is needed as it was shown to be ineffective for severely-exhausted T-cells in the liver in one study [67]
and may require concurrent depletion of Tregs to allow anti-viral T-cell expansion rather than selective
expansion of Tregs [68].
A limitation of first in human Phase I clinical trials is the small number of study participants
(4–5 per arm). The group sizes in this study are typical of those in a phase I study that must balance
the requirement of meeting the study end-points (safety and immunogenicity) with ethical constraints.
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In spite of the small sample sizes, statistically significant differences in immune measurements were
found when comparing vaccinated healthy volunteers and HCV infected patients. To fully assess the
efficacy of this vaccine regimen and the cross-reactivity of vaccine-induced T-cells across a broader
range of HLAs and HCV genotypes, a larger cohort of patients is required. A group of healthy
volunteers were vaccinated with the same regimen (ChAd3-NSmut/MVA-NSmut) as part of this study,
allowing an accurate comparison to be made with the vaccines immunogenicity in HCV infected
patients; however, comparison are also made with historic data from a previous study employing
ChAd3-NSmut/Ad6-NSmut in a heterologous prime-boost vaccine regimen [24]. This is a limitation
to the study, although both trials were performed in the same laboratories, by the same staff, and using
the same experimental setup and reagents, therefore, the relative immunogenicity of these regimens
can be reasonably compared in HCV infected patients.
This work highlights the major challenges in developing an immunotherapy in the setting of
chronic high antigen level and against highly variable pathogens. It is still not clear why T-cells that
do not recognise the circulating virus and, therefore, should not be driven to exhaustion by antigen
exposure, are still partially exhausted when boosted or primed by our virally-vectored vaccines. Nor is
it clear why pre-existing responses, the majority of which also do not target circulating virus, are
not boosted by vaccination, or why T-cells in all patients with the virus that is mismatched to the
vaccine immunogen sequence at a given epitope do not expand on vaccination. The removal of
virus and, therefore, antigen by DAA cure may help to unpick the relative contributions of activation
by chronic inflammation and by a specific cognate antigen. The work described here emphasises
the need for a particularly broad and cross-reactive T-cell response for the effective control of HCV.
These observations are also relevant for vaccine development against other variable pathogens, such as
HIV, and for cancer immunotherapy, where mismatch between vaccine immunogen and endogenous
antigens will commonly arise.
5. Conclusions
In conclusion, we have shown that a highly-potent T-cell vaccine regimen is not able to reconstitute
the HCV-specific T-cell pool during chronic HCV disease and that, for variable viruses, it is essential to
assess recognition of autologous viral sequence by vaccine-induced T-cells.
Supplementary Materials: The following are available online at www.mdpi.com/2076-393X/4/3/27/s1;
Figure S1: Safety data, Figure S2: Phylogenetic tree of HCV whole genome sequences, Figure S3: Anti-vector
immunity, Table S1: Study arms, vaccinations given and dose, treatment given.
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